Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Neuronetics, Inc.

NASDAQ: STIM · Industrial Applications and Services · 9 alerts · CIK 1227636

Share price
$1.25Close, Nov 16
Market cap
$97.2M
Shares outstanding
77.73MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Neuronetics, Inc. filings on SEC EDGAR ↗

9:44 PM ET Form 4
Insider Buying

Neuronetics Insider Jorey Chernett Buys $79.6K of Stock

Jorey Chernett bought 40,000 shares of Neuronetics, Inc. at $1.99 a share, worth $79.6K in total on Nov 9, 2026. Shares held after the trade: 10,306,225 (+0.4%).

Value
$79.6K
Shares
40,000
Price
$1.99
Holding change
+0.4%
Trade date
Nov 9, 2026
9:44 PM ET Form 4
Insider Selling

Neuronetics Insider Jorey Chernett Sells $4.48M of Stock

Jorey Chernett sold 3,335,411 shares of Neuronetics, Inc. at $1.15 to $2.39 a share (average $1.34) in 5 transactions, worth $4.48M in total between Nov 6, 2026 and Nov 13, 2026. Shares held after the trade: 7,325,577 (-23.0%).

Value
$4.48M
Shares
3,335,411
Average price
$1.34
Holding change
-23.0%
Trade date
Nov 6, 2026 to Nov 13, 2026
4:10 PM ET 8-K/A
Capital Raise

Neuronetics Capital Raise of $30M

Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The company also granted underwriters a 30-day option to purchase an additional 2,812,500 shares, bringing the total potential gross proceeds to approximately $34.5 million. Net proceeds will be used to repay a portion of outstanding term loans under its Perceptive Credit Facility and for general corporate purposes.

Value
$30M
Counterparty
William Blair & Company, L.L.C.
8:34 AM ET 8-K
Capital Raise

Neuronetics Capital Raise of $30M

Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at $1.60 per share, with an additional 2,812,500 shares available via an underwriters' option. The company expects to raise approximately $30 million in gross proceeds ($27.7 million net) to repay debt under its Perceptive Credit Facility and for general corporate purposes.

Value
$30M
Counterparty
William Blair & Company, L.L.C.
4:10 PM ET 8-K
Loan & Debt

Neuronetics Debt Financing Update with Perceptive Credit Holdings IV, LP

Neuronetics entered into Amendment No. 6 to its existing Credit Agreement with Perceptive Credit Holdings IV, LP to modify certain revenue covenants. The amendment is subject to an optional prepayment of at least $15 million plus interest and fees, and will automatically terminate if conditions are not met by November 30, 2026.

Counterparty
Perceptive Credit Holdings IV, LP
8:01 AM ET 10-Q
Financial Results ▶ Call

Neuronetics Q3 2026 Results: Net Loss of $1.69M, Loss Narrows

Neuronetics, Inc. reported total revenues of $41.96 million for the quarter ended September 30, 2026, a 12.5% increase over the prior year, driven primarily by growth in the Greenbrook segment. The company achieved a quarterly income from operations of $0.54 million compared to a loss of $7.32 million in the prior year, though it maintained a net loss of $1.56 million for the period.

Key figure
Net loss $1.69M
7:55 AM ET 8-K
Financial Results

Neuronetics Financial Results

Neuronetics reported Q3 2026 total revenue of $42.0 million, a 12.5% increase year-over-year, driven primarily by 20.1% growth in its Greenbrook clinic segment. The company achieved a significant turnaround in profitability, reporting positive Adjusted EBITDA of $1.9 million and income from operations of $0.5 million compared to losses in the prior year period.

Term
Q3 2026

“This quarter showed our strategy taking hold across our business. We delivered a record third quarter within Greenbrook as well as NeuroStar system sales. This reflects both our revenue cycle management advances as well as the positive reception of our expanded NeuroStar go-to-market options. We also continued to demonstrate our prioritization on profitability and cashflow generation.”

Dan Reuvers, President and Chief Executive Officer of Neuronetics
8:50 AM ET Form 4
Insider Buying

Neuronetics Insider Jorey Chernett Buys $40.9K of Stock

Jorey Chernett bought 18,000 shares of Neuronetics, Inc. at $2.27 a share, worth $40.9K in total on Oct 30, 2026. Shares held after the trade: 10,620,988 (+0.2%).

Value
$40.9K
Shares
18,000
Price
$2.27
Holding change
+0.2%
Trade date
Oct 30, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.